前立腺がん治療薬の世界市場予測および分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 15
1.2 List of Figures 20
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 22
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 24
3.1.1 Etiology 24
3.1.2 Pathophysiology 24
3.2 Staging 25
3.3 Symptoms 29
3.4 Prognosis 29
3.5 Quality of Life 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 31
4.3 Global Trends 34
4.3.1 US 35
4.3.2 5EU 36
4.3.3 Japan, Brazil, and Canada 36
4.4 Forecast Methodology 37
4.4.1 Sources Used 38
4.4.2 Sources Not Used 44
4.4.3 Forecast Assumptions and Methods 45
4.5 Epidemiological Forecast for Prostate Cancer (2013-2023) 48
4.5.1 Diagnosed Incident Cases of Prostate Cancer 48
4.5.2 Age-Specific Diagnosed Incident Cases of Prostate Cancer 50
4.5.3 Age-Standardized Diagnosed Incidence of Prostate Cancer 52
4.5.4 Clinical Stage at Diagnosis 54
4.5.5 Diagnosed Five-Year Prevalent Cases of Prostate Cancer 55
4.5.6 Diagnosed Five-Year Prevalent Cases of CRPC 56
4.5.7 Diagnosed Five-Year Prevalent Cases of Bone Metastases Among CRPC Patients 58
4.6 Discussion 60
4.6.1 Epidemiological Forecast Insight 60
4.6.2 Limitations of the Analysis 61
4.6.3 Strengths of the Analysis 62
5 Disease Management 63
5.1 Diagnosis and Treatment Overview 63
5.1.1 Screening and Diagnosis 63
5.1.2 Treatment Guidelines and the Leading Prescribed Drugs 65
5.1.3 Clinical Practice 67
5.2 US 77
5.3 France 78
5.4 Germany 79
5.5 Italy 80
5.6 Spain 81
5.7 UK 82
5.8 Japan 83
5.9 Brazil 84
5.10 Canada 85
6 Competitive Assessment 86
6.1 Overview 86
6.2 Product Profiles – Major Brands, Targeted Therapies 87
6.2.1 Zytiga (abiraterone acetate) 87
6.2.2 Xtandi (enzalutamide) 93
6.2.3 Xofigo (radium 223 dichloride) 98
6.3 Product Profiles – Major Brands, Chemotherapies 104
6.3.1 Jevtana (cabazitaxel) 104
6.4 Product Profiles – Major Brands, Therapeutic Vaccines 108
6.4.1 Provenge (sipuleucel-T) 108
6.5 Product Profiles – Major Brands, Hormone Therapies 112
6.5.1 Zoladex (goserelin acetate) 112
6.5.2 Lupron Depot (leuprolide acetate) 115
6.5.3 Eligard (leuprolide acetate) 118
6.5.4 Trelstar (triptorelin acetate) 120
6.5.5 Firmagon (degarelix) 122
6.5.6 Casodex (bicalutamide) 125
6.6 Product Profiles – Major Brands, Bone Therapies 128
6.6.1 Zometa (zoledronic acid) 128
6.6.2 Xgeva (denosumab) 130
7 Unmet Need and Opportunity 134
7.1 Overview 134
7.2 Therapies That Provide a Durable Overall Survival Benefit for mCRPC Patients 135
7.2.1 Unmet Need 135
7.2.2 Gap Analysis 136
7.2.3 Opportunity 137
7.3 Therapeutic Options for nmCRPC Patients 137
7.3.1 Unmet Need 137
7.3.2 Gap Analysis 138
7.3.3 Opportunity 138
7.4 Identification of Biomarkers to Predict Zytiga and Xtandi Resistance 139
7.4.1 Unmet Need 139
7.4.2 Gap Analysis 140
7.4.3 Opportunity 141
7.5 Defining the Best Sequence of Drugs to Manage mCRPC 141
7.5.1 Unmet Need 141
7.5.2 Gap Analysis 142
7.5.3 Opportunity 143
8 Pipeline Assessment 144
8.1 Overview 144
8.2 Product Profiles − Immunotherapies 147
8.2.1 Yervoy (ipilimumab) 147
8.2.2 ProstVac 153
8.2.3 ProstAtak 158
8.2.4 DCVAC/PCa 163
8.2.5 ITK1 168
8.3 Product Profiles – Targeted Therapies 173
8.3.1 Custirsen Sodium 173
8.3.2 Tasquinimod 178
8.3.3 ARN-509 183
8.3.4 ODM-201 187
9 Current and Future Players 193
9.1 Overview 193
9.2 Trends in Corporate Strategy 195
9.3 Company Profiles 196
9.3.1 Astellas 196
9.3.2 Johnson & Johnson 198
9.3.3 Bayer 200
10 Market Outlook 202
10.1 Global Markets 202
10.1.1 Forecast 202
10.1.2 Drivers and Barriers – Global Issues 206
10.2 US 206
10.2.1 Forecast 206
10.2.2 Key Events 210
10.2.3 Drivers and Barriers 211
10.3 5EU 211
10.3.1 Forecast 211
10.3.2 Key Events 215
10.3.3 Drivers and Barriers 216
10.4 Japan 216
10.4.1 Forecast 216
10.4.2 Key Events 220
10.4.3 Drivers and Barriers 221
10.5 Brazil 221
10.5.1 Forecast 221
10.5.2 Key Events 225
10.5.3 Drivers and Barriers 226
10.6 Canada 226
10.6.1 Forecast 226
10.6.2 Key Events 230
10.6.3 Drivers and Barriers 231
11 Appendix 232
11.1 Bibliography 232
11.2 Abbreviations 251
11.3 Methodology 256
11.4 Forecasting Methodology 256
11.4.1 Diagnosed Prostate Cancer Patients 256
11.4.2 Percentage Drug-Treated Patients 257
11.4.3 Drugs Included in Each Therapeutic Class 257
11.4.4 Launch and Patent Expiry Dates 258
11.4.5 General Pricing Assumptions 259
11.4.6 Individual Drug Assumptions 260
11.4.7 Pricing of Pipeline Agents 263
11.5 Primary Research – KOLs Interviewed for This Report 265
11.6 Primary Research – Prescriber Survey 267
11.7 About the Authors 268
11.7.1 Analyst 268
11.7.2 Director of Oncology 268
11.7.3 Epidemiologist 269
11.7.4 Global Head of Healthcare 269
11.8 About GlobalData 270
11.9 Disclaimer 270